Literature DB >> 30443811

Histologic transformation of non-small-cell lung cancer in brain metastases.

Meng Jiang1, Xiaolong Zhu2, Xiao Han3, Haiyan Jing4, Tao Han1, Qiang Li5, Xiao Ding6.   

Abstract

BACKGROUND: Treatment strategies differ substantially for small-cell lung cancer (SCLC), adenocarcinoma and squamous-cell cancer (SCC). Therefore, it is of important significance to identify histologic transformation. There are no reports on histologic transformation in brain metastases (BM) to date. The aim of this study was to analyze the histologic transformation in BM for the first time.
METHODS: Medical records were reviewed and patients with both resected BM and primary tumors were examined retrospectively. The histologic diagnosis was confirmed by H&E staining, and additional diagnostic immunohistochemical stains were performed at the discretion of the pathologists. Characteristics of histologic transformation in BM were analyzed.
RESULTS: 3 of 24 patients (12.5%) with both resected BM and primary non-small-cell lung cancers (NSCLCs) had evidence of histologic transformation in BM. One case with SCC transformed to adenocarcinoma in brain, one case with adenocarcinoma transformed to SCLC, and another case with adenocarcinoma transformed to SCC. The three cases of histologic transformation were all spontaneous and had not tested gene status.
CONCLUSIONS: We disclosed the histologic transformation of NSCLC in BM at a frequency not as low as expected, and speculated it as an evolution promoted by intratumor heterogeneity, though it warrants further prospective multi-institution investigations with comprehensive molecular analysis. Our findings provided further impetus for surgery when the metastatic or recurrent lesion is resectable, and repeated pathologic evaluation to help tailor individualized treatment.

Entities:  

Keywords:  Brain metastases; Histologic transformation; Non-small-cell lung cancer; Small-cell lung cancer; Surgery

Mesh:

Year:  2018        PMID: 30443811     DOI: 10.1007/s10147-018-1369-1

Source DB:  PubMed          Journal:  Int J Clin Oncol        ISSN: 1341-9625            Impact factor:   3.402


  30 in total

1.  Small cell lung cancer with an epidermal growth factor receptor mutation in primary gefitinib-resistant adenocarcinoma of the lung.

Authors:  Ada T W Ma; Wai Kong Chan; Edmond S K Ma; Thomas Cheng; Paul N M Cheng
Journal:  Acta Oncol       Date:  2011-11-30       Impact factor: 4.089

2.  Transformation to sarcomatoid carcinoma in ALK-rearranged adenocarcinoma, which developed acquired resistance to crizotinib and received subsequent chemotherapies.

Authors:  Yoshihisa Kobayashi; Yukinori Sakao; Simon Ito; Jangchul Park; Hiroaki Kuroda; Noriaki Sakakura; Noriyasu Usami; Tetsuya Mitsudomi; Yasushi Yatabe
Journal:  J Thorac Oncol       Date:  2013-08       Impact factor: 15.609

3.  A patient with simultaneously appearing adenocarcinoma and small-cell lung carcinoma harbouring an identical EGFR exon 19 mutation.

Authors:  S van Riel; E Thunnissen; D Heideman; E F Smit; B Biesma
Journal:  Ann Oncol       Date:  2012-10-18       Impact factor: 32.976

4.  Transformation to "high grade" neuroendocrine carcinoma as an acquired drug resistance mechanism in EGFR-mutant lung adenocarcinoma.

Authors:  S Popat; A Wotherspoon; C M Nutting; D Gonzalez; A G Nicholson; M O'Brien
Journal:  Lung Cancer       Date:  2013-01-10       Impact factor: 5.705

5.  Transformation to small-cell lung cancer following treatment with EGFR tyrosine kinase inhibitors in a patient with lung adenocarcinoma.

Authors:  Satoshi Watanabe; Takashi Sone; Tomoharu Matsui; Kenta Yamamura; Mayuko Tani; Akihito Okazaki; Koji Kurokawa; Yuichi Tambo; Hazuki Takato; Noriyuki Ohkura; Yuko Waseda; Nobuyuki Katayama; Kazuo Kasahara
Journal:  Lung Cancer       Date:  2013-09-05       Impact factor: 5.705

6.  Small-cell carcinoma with an epidermal growth factor receptor mutation in a never-smoker with gefitinib-responsive adenocarcinoma of the lung.

Authors:  Naheed Alam; Karen S Gustafson; Marc Ladanyi; Maureen F Zakowski; Atul Kapoor; Alexander M Truskinovsky; Arkadiusz Z Dudek
Journal:  Clin Lung Cancer       Date:  2010-09-01       Impact factor: 4.785

7.  Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors.

Authors:  Lecia V Sequist; Belinda A Waltman; Dora Dias-Santagata; Subba Digumarthy; Alexa B Turke; Panos Fidias; Kristin Bergethon; Alice T Shaw; Scott Gettinger; Arjola K Cosper; Sara Akhavanfard; Rebecca S Heist; Jennifer Temel; James G Christensen; John C Wain; Thomas J Lynch; Kathy Vernovsky; Eugene J Mark; Michael Lanuti; A John Iafrate; Mari Mino-Kenudson; Jeffrey A Engelman
Journal:  Sci Transl Med       Date:  2011-03-23       Impact factor: 17.956

8.  Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers.

Authors:  Helena A Yu; Maria E Arcila; Natasha Rekhtman; Camelia S Sima; Maureen F Zakowski; William Pao; Mark G Kris; Vincent A Miller; Marc Ladanyi; Gregory J Riely
Journal:  Clin Cancer Res       Date:  2013-03-07       Impact factor: 12.531

9.  Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer.

Authors:  Martin Peifer; Lynnette Fernández-Cuesta; Martin L Sos; Julie George; Danila Seidel; Lawryn H Kasper; Dennis Plenker; Frauke Leenders; Ruping Sun; Thomas Zander; Roopika Menon; Mirjam Koker; Ilona Dahmen; Christian Müller; Vincenzo Di Cerbo; Hans-Ulrich Schildhaus; Janine Altmüller; Ingelore Baessmann; Christian Becker; Bram de Wilde; Jo Vandesompele; Diana Böhm; Sascha Ansén; Franziska Gabler; Ines Wilkening; Stefanie Heynck; Johannes M Heuckmann; Xin Lu; Scott L Carter; Kristian Cibulskis; Shantanu Banerji; Gad Getz; Kwon-Sik Park; Daniel Rauh; Christian Grütter; Matthias Fischer; Laura Pasqualucci; Gavin Wright; Zoe Wainer; Prudence Russell; Iver Petersen; Yuan Chen; Erich Stoelben; Corinna Ludwig; Philipp Schnabel; Hans Hoffmann; Thomas Muley; Michael Brockmann; Walburga Engel-Riedel; Lucia A Muscarella; Vito M Fazio; Harry Groen; Wim Timens; Hannie Sietsma; Erik Thunnissen; Egbert Smit; Daniëlle A M Heideman; Peter J F Snijders; Federico Cappuzzo; Claudia Ligorio; Stefania Damiani; John Field; Steinar Solberg; Odd Terje Brustugun; Marius Lund-Iversen; Jörg Sänger; Joachim H Clement; Alex Soltermann; Holger Moch; Walter Weder; Benjamin Solomon; Jean-Charles Soria; Pierre Validire; Benjamin Besse; Elisabeth Brambilla; Christian Brambilla; Sylvie Lantuejoul; Philippe Lorimier; Peter M Schneider; Michael Hallek; William Pao; Matthew Meyerson; Julien Sage; Jay Shendure; Robert Schneider; Reinhard Büttner; Jürgen Wolf; Peter Nürnberg; Sven Perner; Lukas C Heukamp; Paul K Brindle; Stefan Haas; Roman K Thomas
Journal:  Nat Genet       Date:  2012-09-02       Impact factor: 38.330

10.  Sequential occurrence of non-small cell and small cell lung cancer with the same EGFR mutation.

Authors:  Ryotaro Morinaga; Isamu Okamoto; Kazuyuki Furuta; Yukiko Kawano; Masaru Sekijima; Kensaku Dote; Takao Satou; Kazuto Nishio; Masahiro Fukuoka; Kazuhiko Nakagawa
Journal:  Lung Cancer       Date:  2007-06-29       Impact factor: 5.705

View more
  4 in total

Review 1.  Pathological transition as the arising mechanism for drug resistance in lung cancer.

Authors:  Yueqing Chen; Waiying Yvonne Tang; Xinyuan Tong; Hongbin Ji
Journal:  Cancer Commun (Lond)       Date:  2019-10-01

2.  The development and validation of a nomogram for predicting brain metastases in lung squamous cell carcinoma patients: an analysis of the Surveillance, Epidemiology, and End Results (SEER) database.

Authors:  Jingya Zhang; Jiali Xu; Shidai Jin; Wen Gao; Renhua Guo; Liang Chen
Journal:  J Thorac Dis       Date:  2021-01       Impact factor: 2.895

Review 3.  Central nervous system metastases and oligoprogression during treatment with tyrosine kinase inhibitors in oncogene-addicted non-small cell lung cancer: how to treat and when?

Authors:  Janna Josephus Anna Oda Schoenmaekers; Marthe Sentijna Paats; Anne-Marie Clasina Dingemans; Lizza Elisabeth Lucia Hendriks
Journal:  Transl Lung Cancer Res       Date:  2020-12

4.  Histologic transformation of lung adenocarcinoma to squamous cell carcinoma after chemotherapy: two case reports.

Authors:  Yi Shao; Dian-Sheng Zhong; Sha-Sha Guan
Journal:  Transl Cancer Res       Date:  2020-01       Impact factor: 1.241

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.